Literature DB >> 23156648

Levelling the playing field? Sharing of influenza viruses and access to vaccines and other benefits.

Nicole Jefferies1.   

Abstract

With the adoption of the Pandemic Influenza Preparedness Framework, including its annexes, by the 64th World Health Assembly, this article investigates the disproportionate burden of risk and benefits between resource-poor countries in the developing South and resource-rich industrialised developed nations of the North in the World Health Organisation's Standard Material Transfer Agreement (SMTA) for accessing and sharing influenza viruses. It concludes that the countries of the South have a unique opportunity to level the playing field through providing timely and affordable access to life-saving vaccine and meaningful benefit-sharing that will deliver technology and economic development. Importantly, the article also demonstrates that SMTAs are not merely a redirection of existing resources from North to South but offer a solution to the ongoing shortage of pandemic influenza vaccine by enabling the South to access technology necessary for sustainable vaccine production and thus increasing global vaccine capacity.

Mesh:

Substances:

Year:  2012        PMID: 23156648

Source DB:  PubMed          Journal:  J Law Med        ISSN: 1320-159X


  3 in total

1.  Access by Design, Benefits if Convenient: A Closer Look at the Pandemic Influenza Preparedness Framework's Standard Material Transfer Agreements.

Authors:  Michelle F Rourke
Journal:  Milbank Q       Date:  2019-01-13       Impact factor: 4.911

2.  Negotiating equitable access to influenza vaccines: global health diplomacy and the controversies surrounding avian influenza H5N1 and pandemic influenza H1N1.

Authors:  David P Fidler
Journal:  PLoS Med       Date:  2010-05-04       Impact factor: 11.069

3.  US public support for vaccine donation to poorer countries in the 2009 H1N1 pandemic.

Authors:  Supriya Kumar; Sandra Crouse Quinn; Kevin H Kim; Karen M Hilyard
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.